Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients

Tania Al-Chalabi, William Douglas Figg*

*Corresponding author for this work

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)318-319
Number of pages2
JournalCancer Biology and Therapy
Volume6
Issue number3
DOIs
StatePublished - Mar 2007
Externally publishedYes

Keywords

  • Angiogenesis inhibitors
  • Hormone refractory prostate cancer
  • Oral chemotherapy

Fingerprint

Dive into the research topics of 'Benefits of the combination of thalidomide plus cyclophosphamide in hormone refractory prostate cancer patients'. Together they form a unique fingerprint.

Cite this